Company profile · Sponsor
Eli
Eli Lilly Co.
- Pipeline
- 24
- Drugs
- 0
- Patents
- 0
Quick answer
Eli (E2BD214) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (24)
Search pipeline →-
0.9% sodium chloride, Lepodisiran
Eli
Atherosclerotic Cardiovascular Disease Elevated lp(a)
1 trial -
ABEMACICLIB , FULVESTRANT
Eli
Breast cancer
1 trial -
ANASTROZOLE , PALBOCICLIB , TERSOLISIB, RIBOCICLIB , EXEMESTANE , FULVESTRANT , abemaciclib, TERSOLISIB, TERSOLISIB, TERSOLISIB, LETROZOLE , TERSOLISIB, to match Tersolisib (LY4064809), STX-478
Eli
Neoplasm Metastasis, Breast Neoplasms
1 trial -
BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB
Eli
Uveitis
1 trial -
BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib
Eli
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB
Eli
Juvenile Idiopathic Arthritis
1 trial -
BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB
Eli
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension
Eli
Atopic Dermatitis
1 trial -
Baricitinib
Eli
Covid19 Corona Virus Infection
1 trial -
Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB
Eli
RET-Mutant Medullary Thyroid Cancer
1 trial -
DULAGLUTIDE , Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide
Eli
Type 2 Diabetes Mellitus
1 trial -
Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.
Eli
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders
1 trial -
EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN
Eli
Type 2 Diabetes
1 trial -
Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide
Eli
Overweight, Obesity, Sleep Apnea, Obstructive
1 trial -
Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide
Eli
Overweight, Obesity
1 trial -
Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide
Eli
Obesity, Overweight
1 trial -
FULVESTRANT , EXEMESTANE , ABEMACICLIB
Eli
Breast Cancer
1 trial -
GEMCITABINE , CARBOPLATIN , MIRVETUXIMAB SORAVTANSINE, TOPOTECAN , LY4170156, BEVACIZUMAB , PACLITAXEL , DOXORUBICIN
Eli
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli
Migraine
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli
Chronic Migraine
1 trial -
Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab
Eli
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
1 trial -
Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE
Eli
Perennial Allergic Rhinitis (PAR)
1 trial -
METFORMIN , DAPAGLIFLOZIN
Eli
Type 2 Diabetes
1 trial -
Mirikizumab, Mirikizumab
Eli
Ulcerative Colitis
1 trial
Frequently asked questions
What is Eli?
Eli (E2BD214) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Eli sponsor?
We track 24 ClinicalTrials.gov-linked programs for Eli, including 0.9% sodium chloride, Lepodisiran and 23 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Eli company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.